In 1957, Jean Stern converted the blood glucose-lowering potential of metformin in therapy for T2DM: he observed that, in subjects with maturity-onset diabetes, metformin could replace or reduce the need for insulin without the occurrence of frank hypoglycemia [19,20,21,22,23]. The gene discussed is INS; the disease is type 2 diabetes mellitus.